Trial Profile

Phase-1 Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Utreglutide (Primary)
Indications Obesity
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Sun Pharmaceutical Industries

Most Recent Events

26 Jun 2023 Status changed from planning to recruiting as per results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
26 Jun 2023 Planned number of patients changed to 24.
26 Jun 2023 Results assessing the safety and tolerability of single-ascending doses of GL presented at the 83rd Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com